Swallow this pill to map your gut bugs
NCT ID NCT07243756
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed pilot study tested a 3D-printed ingestible pill designed to trap bacteria from the gut, including the hard-to-reach small intestine. Ten healthy adults swallowed the pill, which passes naturally through the body. Researchers checked safety and how well the pill captured gut bacteria compared to stool samples.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this pill could offer a new way to sample gut bacteria from the small intestine without invasive procedures, improving microbiome research.
- What could go wrong
- This is a very small, early pilot study with only 10 healthy people. The pill may not work well for everyone, and results may not apply to people with gut diseases.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
10 people
The number who actually took part.
- Started
-
Jan 2026
- Finished
-
Apr 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Healthy adults aged 18-65. 2. Willing and able to provide informed consent. 3. Able and willing to comply with study procedures, including pill ingestion, stool collection, follow and record dietary instructions, and fill questionnaires. Exclusion Criteria: 1. History of gastrointestinal diseases (e.g., Crohn's disease, irritable bowel syndrome, small intestinal bacterial overgrowth). 2. History of abdominal surgery that may impact gastrointestinal function (e.g., bowel resection, bariatric surgery). 3. Known allergies or intolerances to medical devices or ingestible capsules. 4. Recent antibiotic use (within 3 months) that may affect gut microbiome results. 5. Use of medications that alter GI motility such as laxatives or prokinetics. 6. Known anatomical abnormalities or strictures in the GI tract that increase the risk of obstruction. 7. Pregnant, planning pregnancy or breastfeeding, since pregnancy and breastfeeding affect the microbiome, Exclusion of pregnancy will be confirmed by the date of the last menstrual period. 8. Participation in another investigational trial within the last 30 days.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NYU Langone Health
New York, New York, 10016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a protein powder with creatine and fiber boost everyday Well-Being?
- Green tech or hidden stress? bus Drivers' hearts monitored behind the wheel
- Shout it out: can growls and screams raise pain tolerance?
- Scientists probe why brain stimulation works for some and not others
- Tiny doses, big questions: how does the body handle this prodrug?
- First human test of CM583: can this biologic pass the safety check?